Cargando…

Patient preferences for chemotherapies used in breast cancer

BACKGROUND: Therapies for invasive breast cancer may be associated with an incremental survival advantage that should be weighed against the risk of toxicities when making treatment decisions. The objective of this study was to elicit patient preferences for a comprehensive profile of attributes ass...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beusterien, Kathleen, Grinspan, Jessica, Tencer, Thomas, Brufsky, Adam, Visovsky, Constance
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3410702/ https://www.ncbi.nlm.nih.gov/pubmed/22870042 http://dx.doi.org/10.2147/IJWH.S31331

Ejemplares similares

Patient preferences in the treatment of diabetic retinopathy
por: Wirostko, Barbara, et al.
Publicado: (2011)

Patient and Neurologist Preferences in the United States for Relapsing-Remitting Multiple Sclerosis Treatments: Findings from a Discrete Choice Experiment
por: Kumar, Jinender, et al.
Publicado: (2021)

Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study
por: Beusterien, Kathleen M, et al.
Publicado: (2010)

Treatment Considerations for the Management of Patients With Hormone Receptor–Positive Metastatic Breast Cancer
por: Visovsky, Constance
Publicado: (2014)

Acupuncture for the Management of Chemotherapy-Induced Peripheral Neuropathy
por: Visovsky, Constance
Publicado: (2012)

Challenges in the Conduct of Research: Chemotherapy-Induced Peripheral Neuropathy
por: Visovsky, Constance
Publicado: (2013)

Psychological distress and quality of life in breast cancer survivors with taxane-induced peripheral neuropathy: A scoping review
por: Schwab, Lauren, et al.
Publicado: (2023)

Real-world experience with colorectal cancer chemotherapies: patient web forum analysis
por: Beusterien, Kathleen, et al.
Publicado: (2013)

Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment
por: Beusterien, Kathleen, et al.
Publicado: (2021)

Nurse Self-Evaluation of Assessment of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer
por: Visovsky, Constance, et al.
Publicado: (2012)

The Challenges of Clinical Research in Rare Cancers: Bevacizumab Use in Low-Grade Serous Ovarian and Primary Peritoneal Cancers
por: Grande, Carolyn, et al.
Publicado: (2017)

Delaying Chemotherapy in the Treatment of Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
por: Brufsky, Adam M.
Publicado: (2015)

Calcium and Magnesium for Oxaliplatin-Induced Neurotoxicity: Issues in Study Design, Measurement, and Analysis
por: Visovsky, Constance
Publicado: (2015)

Writing a Successful Grant: Tips and Tools
por: Visovsky, Constance
Publicado: (2015)

Assessing gait, balance, and muscle strength among breast cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): study protocol for a randomized controlled clinical trial
por: Teran-Wodzinski, Patricia, et al.
Publicado: (2022)

Patient Preferences for Adjuvant Treatment in Muscle-Invasive Urothelial Carcinoma: A Multi-Country Discrete Choice Experiment
por: King-Concialdi, Kristen, et al.
Publicado: (2023)

Adult Patient Preferences for Long-Acting ADHD Treatments: A Discrete Choice Experiment
por: Cambron-Mellott, M Janelle, et al.
Publicado: (2021)

Self-Management of Oxaliplatin-Related Peripheral Neuropathy in Colorectal Cancer Survivors
por: Tofthagen, Cindy, et al.
Publicado: (2013)

Preferences for oral versus intravenous adjuvant chemotherapy among early breast cancer patients
por: Ishitobi, Makoto, et al.
Publicado: (2013)

Japanese patient preferences regarding intermediate to advanced hepatocellular carcinoma treatments
por: Chiba, Tetsuhiro, et al.
Publicado: (2019)

Societal preferences for adjuvant melanoma health states: UK and Australia
por: Middleton, Mark R., et al.
Publicado: (2017)

nab-Paclitaxel for the treatment of breast cancer: an update across treatment settings
por: Brufsky, Adam
Publicado: (2017)

Current Approaches and Emerging Directions in HER2-resistant Breast Cancer
por: Brufsky, Adam M
Publicado: (2014)

Artificial intelligence-directed prognostication of breast cancer
por: Nasrazadani, Azadeh, et al.
Publicado: (2019)

Patient Preferences for Anti-Vascular Endothelial Growth Factor Treatment for Wet Age-Related Macular Degeneration in Japan: A Discrete Choice Experiment
por: Joko, Takeshi, et al.
Publicado: (2020)

A Predictor of Pathological Complete Response to Neoadjuvant Chemotherapy Stratifies Triple Negative Breast Cancer Patients with High Risk of Recurrence
por: Fournier, Marcia V., et al.
Publicado: (2019)

Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer
por: Puhalla, Shannon, et al.
Publicado: (2008)

Patients' preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwhile?
por: Jansen, S J T, et al.
Publicado: (2001)

Peripheral Neuropathy Caused by Paclitaxel and Docetaxel: An Evaluation and Comparison of Symptoms
por: Tofthagen*, Cindy, et al.
Publicado: (2013)

Predictive and Prognostic Value of the 21-Gene Recurrence Score in Hormone Receptor–positive, Node-positive Breast Cancer
por: Brufsky, Adam M.
Publicado: (2014)

Medical Costs and Resource Utilization for Hemophilia Patients With and Without HIV or HCV Infection
por: Tencer, Thomas, et al.
Publicado: (2007)

Prognostic factors and survival of patients with brain metastasis from breast cancer who underwent craniotomy
por: Leone, José Pablo, et al.
Publicado: (2015)

Metastatic Breast Cancer or Multiple Myeloma? Camouflage by Lytic Lesions
por: Hough, Bruce, et al.
Publicado: (2010)

Changes in eating habits and food preferences in breast cancer patients undergoing adjuvant chemotherapy
por: Pedersini, Rebecca, et al.
Publicado: (2021)

Ovarian function suppression as a potential mechanism of chemotherapy
por: Gomez Marti, Juan Luis, et al.
Publicado: (2021)

Barriers to Mesalamine Adherence in Patients with Inflammatory Bowel Disease: A Qualitative Analysis
por: Devlen, Jennifer, et al.
Publicado: (2014)

Adjuvant treatment of HER2-positive breast cancer: winning efforts continue to improve HER2-positive patient outcome long-term
por: Jankowitz, Rachel C, et al.
Publicado: (2012)

Patient Preferences for Chronic Myeloid Leukemia Medication Regimen Attributes and their Potential Impact on Adherence: Results from a Multi-national Conjoint Study
por: Hirji, Ishan, et al.
Publicado: (2014)

P-REALITY X: A Real-World Analysis of Palbociclib Plus an Aromatase Inhibitor in HR+/HER2− Metastatic Breast Cancer—A Podcast
por: Brufsky, Adam, et al.
Publicado: (2023)

Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ef0lnqvk1gkhinisugn2qhqvjs